scholarly journals Intense pustular reaction during treatment of actinic keratosis with ingenol mebutate

2015 ◽  
Vol 3 ◽  
pp. 244-247
Author(s):  
Dorota Jaśkiewicz-Nyckowska ◽  
Zuzanna Lewicka-Potocka ◽  
Aneta Szczerkowska-Dobosz
Keyword(s):  
Actinic Keratosis ◽  
Ingenol Mebutate

scholarly journals Anti-aging effects of ingenol mebutate for patients with actinic keratosis

2018 ◽  
Vol 79 (6) ◽  
pp. 1148-1150 ◽  
Author(s):  
Miri Kim ◽  
Yujin Jung ◽  
Jongsic Kim ◽  
Seo-won Jeong ◽  
Yu Ri Woo ◽  
...  
Keyword(s):  
Actinic Keratosis ◽  
Ingenol Mebutate ◽  
Aging Effects

scholarly journals Efficacy of ingenol mebutate gel for actinic keratosis in patients treated by thiazide diuretics

2016 ◽  
Vol Volume 9 ◽  
pp. 405-409 ◽  
Author(s):  
Elena Campione ◽  
Monia Di Prete ◽  
Laura Diluvio ◽  
Luca Bianchi ◽  
Augusto Orlandi
Keyword(s):  
Actinic Keratosis ◽  
Thiazide Diuretics ◽  
Ingenol Mebutate

Real-life efficacy and safety of ingenol mebutate for the treatment of actinic keratosis of the face and scalp: A single arm retrospective study

2016 ◽  
Vol 27 (6) ◽  
pp. 525-530 ◽  
Author(s):  
Francesco Ricci ◽  
Sara Tambone ◽  
Luca Neri ◽  
Luca Fania ◽  
Antonella Piccioni ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Actinic Keratosis ◽  
Real Life ◽  
Efficacy And Safety ◽  
Ingenol Mebutate ◽  
The Face

scholarly journals A Systematic Review and Meta-Analysis of Interventions for Actinic Keratosis from Post-Marketing Surveillance Trials

2020 ◽  
Vol 9 (7) ◽  
pp. 2253
Author(s):  
Theresa Steeb ◽  
Anja Wessely ◽  
Matthias Harlaß ◽  
Franz Heppt ◽  
Elias A. T. Koch ◽  
...  
Keyword(s):  
Actinic Keratosis ◽  
Meta Analysis ◽  
Diclofenac Sodium ◽  
Total Sample ◽  
Random Effects Model ◽  
Ingenol Mebutate ◽  
Surveillance Studies ◽  
Relative Risks ◽  
Post Marketing Surveillance ◽  
Post Marketing

Multiple interventions are available for the treatment of actinic keratosis (AK) showing high efficacy in pivotal trials. However, data from post-marketing surveillance studies have received little attention until now. Here, we systematically investigate interventions for AK from post-marketing surveillance trials as a proxy for real-world efficacy and tolerability. A systematic literature search was conducted in Medline, Embase, and CENTRAL. Pertinent trial registers were hand-searched until 25 March 2020. Results were pooled using a random-effects model to calculate pooled proportions and relative risks (RR) or were described qualitatively. Eleven records with a total sample size of n = 4109 were included. Three of the studies had an active-controlled design, while seven were single-armed. Participant complete clearance ranged from 23.1% for diclofenac sodium 3% gel to 88.9% for ingenol mebutate 0.05% gel. The lesion-specific clearance rate for photodynamic therapy (PDT) was 74% (95% confidence interval (CI) 56–87%). The recurrence rate was significantly higher for diclofenac sodium 3% in comparison to imiquimod 5% cream (RR 1.10, 95% CI 1.02–1.1.8) and ranged from 10.6% for ingenol mebutate 0.015% gel to 23.5% for PDT. Few patients discontinued the trials due to adverse events. The results from the majority of the post-marketing surveillance studies deviated from those of pivotal trials.

scholarly journals Cost-Utility Analysis of Ingenol Mebutate Versus Imiquimod 5% for Actinic Keratosis Treatment In Spain

2015 ◽  
Vol 18 (7) ◽  
pp. A423 ◽  
Author(s):  
N Ortega-Joaquin ◽  
I Elías ◽  
P de la Cueva ◽  
LJ Del Pozo ◽  
A Boada ◽  
...  
Keyword(s):  
Actinic Keratosis ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Ingenol Mebutate ◽  
Utility Analysis
Sign in / Sign up

Export Citation Format

Share Document